BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30033448)

  • 41. Renal cell carcinoma: resistance to therapy, role of apoptosis, and the prognostic and therapeutic target potential of TRAF proteins.
    Rajandram R; Bennett NC; Morais C; Johnson DW; Gobe GC
    Med Hypotheses; 2012 Feb; 78(2):330-6. PubMed ID: 22153576
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
    Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
    BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Protein Kinase RNA-Like Endoplasmic Reticulum Kinase-Mediated Bcl-2 Protein Phosphorylation Contributes to Evodiamine-Induced Apoptosis of Human Renal Cell Carcinoma Cells.
    Wu WS; Chien CC; Chen YC; Chiu WT
    PLoS One; 2016; 11(8):e0160484. PubMed ID: 27483435
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Notch signaling plays a crucial role in cancer stem-like cells maintaining stemness and mediating chemotaxis in renal cell carcinoma.
    Xiao W; Gao Z; Duan Y; Yuan W; Ke Y
    J Exp Clin Cancer Res; 2017 Mar; 36(1):41. PubMed ID: 28279221
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CNPY2 promoted the proliferation of renal cell carcinoma cells and increased the expression of TP53.
    Taniguchi H; Ito S; Ueda T; Morioka Y; Kayukawa N; Ueno A; Nakagawa H; Fujihara A; Ushijima S; Kanazawa M; Hongo F; Ukimura O
    Biochem Biophys Res Commun; 2017 Apr; 485(2):267-271. PubMed ID: 28235487
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PBRM1 (BAF180) protein is functionally regulated by p53-induced protein degradation in renal cell carcinomas.
    Macher-Goeppinger S; Keith M; Tagscherer KE; Singer S; Winkler J; Hofmann TG; Pahernik S; Duensing S; Hohenfellner M; Kopitz J; Schirmacher P; Roth W
    J Pathol; 2015 Dec; 237(4):460-71. PubMed ID: 26178300
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo.
    Zou Y; Wang J; Leng X; Huang J; Xue W; Zhang J; Huang Y
    Oncotarget; 2017 Mar; 8(13):20825-20833. PubMed ID: 28212559
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
    Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
    Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of BRD4 Suppresses Cell Proliferation and Induces Apoptosis in Renal Cell Carcinoma.
    Wu X; Liu D; Gao X; Xie F; Tao D; Xiao X; Wang L; Jiang G; Zeng F
    Cell Physiol Biochem; 2017; 41(5):1947-1956. PubMed ID: 28391274
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ATF2 predicts poor prognosis and promotes malignant phenotypes in renal cell carcinoma.
    Wu DS; Chen C; Wu ZJ; Liu B; Gao L; Yang Q; Chen W; Chen JM; Bao Y; Qu L; Wang LH
    J Exp Clin Cancer Res; 2016 Jul; 35(1):108. PubMed ID: 27377902
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Migration of renal carcinoma cells is dependent on protein kinase Cdelta via beta1 integrin and focal adhesion kinase.
    Brenner W; Greber I; Gudejko-Thiel J; Beitz S; Schneider E; Walenta S; Peters K; Unger R; Thüroff JW
    Int J Oncol; 2008 May; 32(5):1125-31. PubMed ID: 18425341
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sorafenib with doxorubicin augments cytotoxicity to renal cell cancer through PERK inhibition.
    Shiota M; Eto M; Yokomizo A; Tada Y; Takeuchi A; Masubuchi D; Inokuchi J; Tatsugami K; Kuroiwa K; Uchiumi T; Seki N; Naito S
    Int J Oncol; 2010 Jun; 36(6):1521-31. PubMed ID: 20428777
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long non-coding RNA HOTAIR promotes cell migration by upregulating insulin growth factor-binding protein 2 in renal cell carcinoma.
    Katayama H; Tamai K; Shibuya R; Nakamura M; Mochizuki M; Yamaguchi K; Kawamura S; Tochigi T; Sato I; Okanishi T; Sakurai K; Fujibuchi W; Arai Y; Satoh K
    Sci Rep; 2017 Sep; 7(1):12016. PubMed ID: 28931862
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-κB signaling in human renal clear cell carcinoma.
    Shang D; Han T; Xu X; Liu Y
    Int J Clin Exp Pathol; 2015; 8(9):11140-8. PubMed ID: 26617834
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
    Chang YS; Adnane J; Trail PA; Levy J; Henderson A; Xue D; Bortolon E; Ichetovkin M; Chen C; McNabola A; Wilkie D; Carter CA; Taylor IC; Lynch M; Wilhelm S
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):561-74. PubMed ID: 17160391
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
    Iguchi M; Matsumoto M; Hojo K; Wada T; Matsuo Y; Arimura A; Abe K
    Jpn J Clin Oncol; 2009 May; 39(5):303-9. PubMed ID: 19336449
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.
    Liu L; Xu Z; Zhong L; Wang H; Jiang S; Long Q; Xu J; Guo J
    BJU Int; 2016 Feb; 117(2):351-62. PubMed ID: 24612432
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interleukin-6 induces drug resistance in renal cell carcinoma.
    Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y
    Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Apigenin inhibits renal cell carcinoma cell proliferation.
    Meng S; Zhu Y; Li JF; Wang X; Liang Z; Li SQ; Xu X; Chen H; Liu B; Zheng XY; Xie LP
    Oncotarget; 2017 Mar; 8(12):19834-19842. PubMed ID: 28423637
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.
    Xu YX; Redon V; Yu H; Querbes W; Pirruccello J; Liebow A; Deik A; Trindade K; Wang X; Musunuru K; Clish CB; Cowan C; Fizgerald K; Rader D; Kathiresan S
    Atherosclerosis; 2018 Jan; 268():196-206. PubMed ID: 29183623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.